Enjoy complimentary customisation on priority with our Enterprise License!
The beta lactam and beta lactamase inhibitors market size is forecast to increase by USD 10.06 billion at a CAGR of 5.47% between 2024 and 2028. The market is witnessing significant growth due to several key trends. One of the primary factors driving market growth is the rising focus on novel drug development to combat the increasing antibiotic resistance. Technological advancements in antibiotic discovery, such as the use of artificial intelligence and machine learning, are also contributing to market growth. Additionally, the emergence of carbapenem-resistant Enterobacteriaceae (CRE) has created a pressing need for effective beta lactam and beta lactamase inhibitor combinations. This trend is expected to continue as the global health community works to address the growing threat of antibiotic resistance. The market is also being influenced by regulatory initiatives aimed at accelerating the development and approval of new antibiotics.
Overall, these factors are expected to fuel market growth and create new opportunities for market participants.
Beta lactam antibiotics are a significant class of antibacterial agents widely used in the medical industry to combat various microorganisms. This drug class includes penicillin, cephalosporin, carbapenem, and monobactam. The market for beta lactam antibiotics continues to grow due to their effectiveness against a broad spectrum of microorganisms. New molecules and combination therapies are being developed to address the increasing resistance of microorganisms to existing beta lactam antibiotics. Cephalosporin, an oral beta lactam antibiotic, is commonly used in the treatment of chronic diseases and for the elderly population. Clinical trials are ongoing to evaluate the safety and efficacy of new beta lactam antibiotics and combination therapies.
The beta lactamase inhibitors market is also expanding as these inhibitors are used to enhance the activity of beta lactam antibiotics against bacteria that produce beta-lactamases. Combination therapies using beta lactam antibiotics and beta-lactamase inhibitors are gaining popularity due to their ability to overcome antibiotic resistance. Overall, the beta lactam and beta-lactamase inhibitors market is expected to grow due to the increasing prevalence of bacterial infections and the need for effective antibiotics to treat them.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The Oral segment is estimated to witness significant growth during the forecast period.ai_market_segmentation_by.multip
Get a glance at the market share of various segments Request Free Sample
The Oral segment accounted for USD 12.59 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 35% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
The market in North America is witnessing significant growth due to the increasing prevalence of infectious diseases, particularly in the elderly population. This demographic is more susceptible to infections, including urinary tract, respiratory, and skin infections, as well as nosocomial pneumonia, blood stream infections, and hospital-acquired pneumonia. These infections often require antibacterial agents such as Penicillin, Cephalosporin, Carbapenem, Monobactam, and their respective inhibitors. The combination of these drug classes is increasingly being used to combat antibiotic resistance, a major challenge in infectious disease treatment. Clinical trials are ongoing for new molecules and combination therapies to address this issue. The North American market for these antibiotics is driven by the region's advanced healthcare infrastructure, which includes well-equipped hospitals, research facilities, and pharmaceutical companies.
The intravenous and oral administration routes are commonly used for treating various infections. As the infectious disease prevalence increases, particularly in the elderly population, the demand for effective antibacterial agents is expected to continue. Creative Diagnostics plays a crucial role in providing reliable and accurate solutions for antibiotic susceptibility testing, enabling effective treatment strategies and improving patient outcomes.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Rising focus on novel drug development is the key driver of the market. Pharmaceutical companies are actively engaged in the research and development of next-generation beta lactam antibiotics and beta lactamase inhibitors to address the rising issue of antibiotic resistance among microorganisms. These antibacterial agents, which include penicillin, cephalosporin, carbapenem, and monobactam, are essential in treating various infectious diseases such as urinary tract infections, respiratory infections, and skin infections. New molecules and combination therapies are being explored to improve the efficacy, broaden the spectrum of activity, and enhance resistance profiles of these drugs. For instance, Pfizer Inc.'s investigational antibiotic combination, aztreonam-avibactam (ATM-AVI), has shown promising results in phase 3 studies, demonstrating effectiveness and tolerability against Gram-negative bacteria.
This combination therapy consists of aztreonam, a monobactam beta-lactam, and avibactam, a new broad-spectrum beta-lactamase inhibitor. The elderly population, who are more susceptible to chronic diseases and hospital-acquired infections like nosocomial pneumonia, blood stream infection, hospital-acquired pneumonia, and ventilator-associated pneumonia, stand to benefit significantly from such advancements. The amalgamation of these traits in new drugs is crucial in overcoming resistance mechanisms and targeting resistant bacterial strains, thereby addressing unmet medical needs in infectious disease management.
Technological advancements in antibiotic discovery is the upcoming trend in the market. The market encompasses the development and use of antibacterial agents that inhibit the action of beta-lactamases produced by microorganisms, thereby enhancing the efficacy of antibiotics such as Penicillin, Cephalosporin, Carbapenem, and Monobactam. With the rising prevalence of infectious diseases and antibiotic resistance, the need for new molecules and combination therapies is increasingly significant. Technological advancements, including High-throughput screening (HTS) techniques and computational modeling methods like molecular docking and virtual screening, expedite the identification and optimization of beta lactam antibiotics and beta lactamase inhibitors. These innovations contribute to the discovery of improved potency and efficacy agents, addressing antibiotic resistance in various clinical applications, such as urinary tract infections, respiratory infections, skin infections, nosocomial pneumonia, blood stream infections, hospital-acquired pneumonia, and ventilator-associated pneumonia.
The elderly population, with its increased susceptibility to chronic diseases, further emphasizes the importance of effective antibiotic treatments. The amalgamation of these traits in beta lactam and beta lactamase inhibitors plays a crucial role in combating the challenges of antibiotic resistance and infectious diseases.
Emergence of carbapenem-resistant Enterobacteriaceae (CRE) is key challenge affecting the market growth. Beta lactam antibiotics, including penicillin, cephalosporin, carbapenem, and monobactam, are essential antibacterial agents used to combat various microorganisms causing infectious diseases. However, the emergence of beta-lactamase producing bacteria, particularly Carbapenem-resistant Enterobacteriaceae (CRE), poses a significant challenge in clinical settings. These strains exhibit resistance to carbapenem antibiotics, which are often considered last-resort treatments for serious bacterial infections. The prevalence of infectious diseases, particularly in the elderly population, and the increasing incidence of chronic diseases necessitate the development of new molecules and combination therapies. The resistance of CREs to various antibiotics limits treatment options, leading to challenges in managing infections caused by these multidrug-resistant pathogens.
Infections caused by CREs are associated with higher rates of mortality and morbidity compared with susceptible bacterial strains. Moreover, CREs are commonly associated with healthcare settings, including hospitals, long-term care facilities, and intensive care units. Nosocomial transmission of CREs among patients can lead to outbreaks and healthcare-associated infections, further complicating infection control efforts and increasing the risk of dissemination within healthcare facilities. The development of new beta-lactamase inhibitors is crucial to combat the growing threat of antibiotic resistance and improve patient outcomes. Clinical trials for new beta-lactamase inhibitors are underway to address the unmet medical need for effective treatments against CREs.
These inhibitors are designed to enhance the activity of beta-lactam antibiotics by inhibiting the action of beta-lactamases produced by resistant bacteria. The use of these inhibitors in combination therapies offers a promising approach to managing infections caused by CREs. Beta-lactamase inhibitors can be administered via various routes, including intravenous and oral, depending on the severity of the infection and the patient's condition. The amalgamation of beta-lactam antibiotics and beta-lactamase inhibitors can significantly improve clinical outcomes in various infections, including urinary tract infections, respiratory infections, skin infections, nosocomial pneumonia, bloodstream infections, hospital-acquired pneumonia, and ventilator-associated pneumonia. Creative Diagnostics is committed to providing high-quality beta-lactamase inhibitors for research and diagnostic applications, contributing to the advancement of antibiotic research and development.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc. - Our company provides a range of beta lactam and beta lactamase inhibitors, including TAZIRA LYO VIAL. These pharmaceutical solutions are essential in the treatment of numerous hospital-acquired and ventilator-associated infections, such as pneumonia and urinary tract infections, as well as intra-abdominal infections. Beta lactam antibiotics, like TAZIRA LYO VIAL, are widely used due to their effectiveness against a broad spectrum of bacteria. However, the emergence of bacterial strains resistant to beta lactam antibiotics has necessitated the co-administration of beta lactamase inhibitors to prevent the deactivation of these antibiotics by the speciallity enzyme beta-lactamase. By offering both beta lactam antibiotics and beta lactamase inhibitors, our company aims to address the growing challenge of antibiotic resistance in healthcare settings.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Beta lactam antibiotics, as a significant antibacterial agent, continue to dominate the infectious disease landscape due to their efficacy against a broad spectrum of microorganisms. Penicillin, cephalosporin, carbapenem, monobactam, and other beta lactam antibiotics are commonly used to treat various infections, including urinary tract, respiratory, and skin infections, as well as nosocomial pneumonia, bloodstream infections, hospital-acquired pneumonia, and ventilator-associated pneumonia. The market for beta lactam antibiotics is driven by the prevalence of infectious diseases, the increasing elderly population, and the rising incidence of antibiotic resistance. New molecules and combination therapies are being developed to address the growing concern of antibiotic resistance.
The drug class is available in various routes of administration, including intravenous and oral forms. Beta lactamase inhibitors are often used in combination with beta lactam antibiotics to enhance their efficacy against bacteria that produce beta-lactamases, enzymes that inactivate beta lactam antibiotics. The combination therapies offer improved clinical outcomes and reduced risk of treatment failures. The creative diagnostics market for beta lactamase detection is also expected to grow due to the increasing need for rapid and accurate identification of beta-lactamase producing bacteria.
Market Scope |
|
Report Coverage |
Details |
Page number |
179 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.47% |
Market growth 2024-2028 |
USD 10.06 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
4.73 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 35% |
Key countries |
US, Germany, UK, China, and India |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Alkem Laboratories Ltd., Astellas Pharma Inc., Cipla Ltd., GlaxoSmithKline Plc, Jaiwik Biotech, Lupin Ltd., MedPlus Health Services Ltd., Meiji Holdings Co. Ltd., Merck KGaA, Novartis AG, Numera Life Sciences, Pfizer Inc., Sandoz AG, Sanofi SA, Spero Therapeutics, Taj Pharmaceutical Ltd., Zeelab Laboratories Ltd., Abbott Laboratories, and F. Hoffmann La Roche Ltd. |
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Market Segmentation by Drug Class
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.